Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Diabetes Trials Could Include Hypoglycemia As Patient-Reported Outcome

Executive Summary

FDA, industry and patient advocates all want studies to move beyond HbA1c, but still need to develop common thresholds and definitions to support patient-reported outcomes in diabetes drug development.


Related Content

Quality-Of-Life, Emotional Well-Being Becoming Highly Utilized PROs In Diabetes Trials
Diabetes Trials Tend To Eschew Patient-Reported Outcomes
Diabetes Outcomes Trial Requirement Looks 'Increasingly Wise' – FDA’s Temple
Diabetes Drug Safety Might Be Best Assessed With Real-World Data
Will CV Verdicts For Onglyza, Nesina Cause FDA To Change Its Tune On Antidiabetic Safety?


Related Companies